Parr Mcknight Wealth Management Group LLC Invests $1.57 Million in Sanofi (NASDAQ:SNY)

Parr Mcknight Wealth Management Group LLC bought a new stake in Sanofi (NASDAQ:SNY) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 32,646 shares of the company’s stock, valued at approximately $1,574,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its position in Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock worth $522,991,000 after acquiring an additional 5,091,304 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Sanofi during the 4th quarter worth $135,933,000. Boston Partners grew its stake in shares of Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after purchasing an additional 2,501,073 shares during the period. Magnetar Financial LLC increased its holdings in shares of Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after purchasing an additional 1,705,148 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in shares of Sanofi by 969.6% in the fourth quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company’s stock valued at $45,850,000 after purchasing an additional 861,770 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SNY has been the topic of a number of research analyst reports. BNP Paribas began coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 price objective on the stock. Hsbc Global Res upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group initiated coverage on Sanofi in a research report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target for the company. Three analysts have rated the stock with a hold rating, two have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi currently has an average rating of “Buy” and an average target price of $63.33.

Sanofi Trading Down 1.0%

Shares of SNY opened at $51.98 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The stock has a market cap of $131.32 billion, a price-to-earnings ratio of 20.88, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55. The firm has a 50 day simple moving average of $52.78 and a 200-day simple moving average of $51.88.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter last year, the business posted $1.78 earnings per share. Sanofi’s revenue was down 11.0% compared to the same quarter last year. Equities analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a dividend of $2.0369 per share. This represents a yield of 3.1%. The ex-dividend date is Friday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.48. Sanofi’s dividend payout ratio (DPR) is currently 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.